Q2 2026 Amneal Pharmaceuticals Inc Earnings Call Transcript
Key Points
- Amneal Pharmaceuticals Inc (AMRX) delivered strong Q2 2026 results with revenue of $796 million, adjusted EBITDA of $206 million, and adjusted EPS of $0.30, marking the seventh consecutive year of top and bottom-line growth.
- The pending acquisition of Kashiv will create a fully integrated global biosimilar platform, with a pipeline of over 20 programs and a clear path to capturing $400-$500 million in financial benefits.
- Specialty products CREXONT and Brekiya continue to show strong uptake, with CREXONT gaining traction as a potential first-line Parkinson's treatment and Brekiya addressing unmet needs in migraine and cluster headache.
- The affordable medicines pipeline is robust, with high-value launches like lanreotide (expected in Q3), iohexol, and romidepsin, supported by complex manufacturing and strong customer relationships.
- Operational excellence is highlighted by the FDA PreCheck pilot program selection for the Brookhaven site, expansion in women's health transdermal patches, and a 50 basis point reduction in Term Loan B interest expense, saving $12 million annually.
- A severe flood at a manufacturing facility in Gujarat, India, is expected to cause a limited impact on select products and an estimated $20 million negative impact on 2026 guidance.
- The Kashiv acquisition, while promising, introduces integration risks and requires significant capital expenditure, with CapEx guidance raised to $150 million to capitalize on near-term opportunities.
- AvKARE revenue declined 4% in Q2, driven by weakness in the low-margin distribution business, partially offset by growth in the government channel.
- The launch of the Xolair biosimilar is delayed to late 2026 or early 2027, with no revenue contribution expected in the current year, potentially impacting near-term biosimilar growth.
- Tariff and regulatory uncertainties from recent administration announcements pose potential risks to the industry, though Amneal's US manufacturing footprint may mitigate some impact.
Good morning, and welcome to the Amneal Pharmaceuticals second quarter 2026 earnings call. I will now turn the call over to Amneal's Head of Investor Relations, Tony DiMeo.
Good morning, and thank you for joining Amneal Pharmaceuticals second quarter 2026 earnings call. Today, we issued a press release reporting Q2 results. The earnings press release and presentation are available on the IR page of amneal.com.
Certain statements made on this call regarding matters that are not historical facts, including but not limited to management's outlook or predictions, are forward-looking statements that are based solely on information that is now available to us. Please see the sections entitled Cautionary Statements on Forward-Looking Statements in our press release and presentation for factors that may impact future performance.
We also discuss non-GAAP measures. Information on use of these measures and reconciliation to GAAP are in the earnings release and presentation.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
